Quote:

---

I believe that during one of the calls in September Nader was asked about an update on enrollment figures, after he gave the number also offered that the speed had slowed down as Dr Dhody was busy doing analysis. Just in the back of my mind.

---

First, let me say that I have absolutely no personal or professional experience in this realm.

However, I would be very surprised to learn that the enrollment rate of a trial being conducted at well-over a dozen sites is entirely contingent on the availability of a Vice President of Clinical Operations.

Source Link: https://www.linkedin.com/in/kush-dhody-mbbs-ms-ccra-309bba3

I have to assume that the Principal Investigators at each trial site location have enough autonomy that they don't have to go running back to Amarex in order to intake a patient.

CytoDyn cannot be Amarex's only client, so does that mean Kush was unavailable for all of the other trials being conducted? Also, if that were SOP (Standard Operating Procedure), I would think it would be impossible for clinical trials to be conducted that included thousands or tens of thousands of patients.

I suspect Dr.NP was spin-doctoring the reason why enrollment had fallen off the cliff.